Dorleans Audrey, Knossow Marcel, Gigant Benoît
Laboratoire d'Enzymologie et Biochimie Structurales, CNRS, Gif-sur-Yvette, France.
Methods Mol Med. 2007;137:235-43. doi: 10.1007/978-1-59745-442-1_16.
Tubulin, the microtubule building-block, is the target of numerous small molecule compounds that interfere with microtubule dynamics. Several of these ligands are in clinical use as antitumor drugs. There have been numerous studies on these molecules, with two main objectives: to determine their mechanism of action and to find new compounds that would expand the arsenal available for cancer chemotherapy. Although these studies would undoubtedly benefit from structural data on tubulin, this protein has long resisted crystallization attempts. We have used stathmin-like domains (SLDs) of stathmin family proteins as a tool to crystallize tubulin and have obtained three-dimensional crystals of the tubulin:SLD complexes. As many tubulin ligands bind to these complexes, the crystals are valuable tools to study tubulin-drug interactions by X-ray crystallography. They open the way to a structure-based drug design approach.
微管蛋白是微管的组成成分,是众多干扰微管动力学的小分子化合物的作用靶点。其中几种配体作为抗肿瘤药物已在临床中使用。针对这些分子已经开展了大量研究,主要有两个目标:确定其作用机制,并寻找能够扩充癌症化疗可用药物库的新化合物。尽管这些研究无疑会受益于微管蛋白的结构数据,但长期以来,这种蛋白质一直难以结晶。我们利用stathmin家族蛋白的类stathmin结构域(SLD)作为使微管蛋白结晶的工具,获得了微管蛋白:SLD复合物的三维晶体。由于许多微管蛋白配体与这些复合物结合,这些晶体是通过X射线晶体学研究微管蛋白-药物相互作用的宝贵工具。它们为基于结构的药物设计方法开辟了道路。